These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3937785)

  • 1. Anticytoskeleton autoantibodies and chronic graft versus host disease.
    Gobbi M; Tazzari P; Tassinari A; Bandini G; Zauli D; Crespi C; Miserocchi F; Tura S
    Haematologica; 1985; 70(5):457-8. PubMed ID: 3937785
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
    Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
    Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Graft failure and graft-vs-host disease after subtotal T-cell-depleted marrow transplantation: correlations with marrow hematopoietic and lymphoid subsets.
    Przepiorka D; Huh YO; Khouri I; Reading C; Hester J; Marshall M; Champlin RE
    Prog Clin Biol Res; 1994; 389():557-63. PubMed ID: 7700921
    [No Abstract]   [Full Text] [Related]  

  • 4. Sonography of the gallbladder in bone marrow transplant patients.
    Frick MP; Snover DC; Feinberg SB; Salomonowitz E; Crass JR; Ramsay NK
    Am J Gastroenterol; 1984 Feb; 79(2):122-7. PubMed ID: 6364795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Bases of bone marrow transplantation: modalities and indications].
    García Laraña J
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():14-21. PubMed ID: 10422446
    [No Abstract]   [Full Text] [Related]  

  • 6. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A trend towards an increased incidence of chronic graft-versus-host disease following allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
    Scott MA; Gandhi MK; Jestice HK; Mahendra P; Bass G; Marcus RE
    Bone Marrow Transplant; 1998 Aug; 22(3):273-6. PubMed ID: 9720741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion.
    Orsini E; Alyea EP; Schlossman R; Canning C; Soiffer RJ; Chillemi A; Neuberg D; Anderson KC; Ritz J
    Bone Marrow Transplant; 2000 Mar; 25(6):623-32. PubMed ID: 10734296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-mitosin antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Muro Y; Kamimoto T; Hagiwara M
    Bone Marrow Transplant; 1997 May; 19(9):951-3. PubMed ID: 9156273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation.
    Winston DJ; Antin JH; Wolff SN; Bierer BE; Small T; Miller KB; Linker C; Kaizer H; Lazarus HM; Petersen FB; Cowan MJ; Ho WG; Wingard JR; Schiller GJ; Territo MC; Jiao J; Petrarca MA; Tonetta SA
    Bone Marrow Transplant; 2001 Jul; 28(2):187-96. PubMed ID: 11509937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. "Altered immunity syndrome", a distinct entity in long-term bone marrow transplantation survivors?
    Trendelenburg M; Gregor M; Passweg J; Tichelli A; Tyndall A; Gratwohl A
    Bone Marrow Transplant; 2001 Dec; 28(12):1175-6. PubMed ID: 11803364
    [No Abstract]   [Full Text] [Related]  

  • 13. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Innsbruck results of bone marrow transplantation in treatment of hematologic neoplasms and solid tumors].
    Nachbaur D; Schwaighofer H; Thaler J; Weyrer W; Fink M; Nussbaumer W; Fritsch E; Niederwieser D
    Wien Klin Wochenschr; 1994; 106(7):201-7. PubMed ID: 8197754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Acute graft-versus-host disease in allogeneic bone marrow transplantation].
    Harada M; Funada H; Yoshida T; Kodo H; Mori T; Matsue K; Shiobara S; Ohtake S; Odaka K; Teshima H
    Rinsho Ketsueki; 1984 Jul; 25(7):1043-51. PubMed ID: 6389930
    [No Abstract]   [Full Text] [Related]  

  • 17. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies].
    Michallet M; Dhedin N; Michallet AS
    Bull Cancer; 2001 Sep; 88(9):908-26. PubMed ID: 11604365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Passive donor-to-recipient transfer of antiphospholipid syndrome following allogeneic stem-cell transplantation.
    Ritchie DS; Sainani A; D'Souza A; Grigg AP
    Am J Hematol; 2005 Aug; 79(4):299-302. PubMed ID: 16044450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
    Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
    Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.